-Reuters
CohBar Announces CB4211 Phase 1a/1b Results Selected For Late Breaker Presentation At The Liver Meeting 2021
CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that data from its CB4211 Phase 1a/1b